{"filing":{"accession_number":"0001193125-26-330644","cik":"0001674416","ticker":"CRSP","company_name":"CRISPR Therapeutics AG","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"crsp-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/crsp-20260803.htm"},"events":[{"id":23125,"run_id":20927,"accession_number":"0001193125-26-330644","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a quarterly earnings release for Q2 2026 disclosing financial results for the period ended June 30, 2026. The filing explicitly states \"CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results\" and includes key financial metrics (CASGEVY revenue of $76 million with 78% QoQ and 151% YoY growth, R\u0026D expenses of $67.2 million, net loss of $91.2 million, and cash position of $2,364.4 million), along with operational highlights and pipeline updates. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23272,"accession_number":"0001193125-26-330644","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results for the period ended June 30, 2026. The filing explicitly states \"CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results\" and includes key financial metrics (CASGEVY revenue of $76 million with 78% QoQ and 151% YoY growth, R\u0026D expenses of $67.2 million, net loss of $91.2 million, and cash position of $2,364.4 million), along with operational highlights and pipeline updates. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:34:18.819420+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23272,"accession_number":"0001193125-26-330644","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results for the period ended June 30, 2026. The filing explicitly states \"CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results\" and includes key financial metrics (CASGEVY revenue of $76 million with 78% QoQ and 151% YoY growth, R\u0026D expenses of $67.2 million, net loss of $91.2 million, and cash position of $2,364.4 million), along with operational highlights and pipeline updates. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:34:18.819420+00:00","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-08-03"}]}